Remo CRO


Ocular Therapeutix publishes positive results of Dextenza following cataract surgery

03.16 2017.

Ocular Therapeutix, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, has announced positive results of a patient experience study of Dextenza (dexamethasone insert) 0.4mg for intracanalicular use. The study, published in Patient Preference and Adherence, evaluated the overall patient experience and perceived value […] Details

New clinical guideline issued for treating low back pain

03.16 2017.

The American College of Physicians have just issued their clinical practice guideline for the noninvasive treatment of nonradicular low back pain. Details

Sites Miss Reimbursable Clinical Trial Costs with Careless Billing Contracts

03.16 2017.

Clinical trial sites, intimidated by billing complexity, often leave money on the table because they are afraid they will make a mistake when they set up a contract, several experts at Kelly Willenberg & Associates Inc. say. “They get paralyzed because they are afraid of billing for something they should not,” says Cynthia Lawson, a […] Details

Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy

03.16 2017.

KENILWORTH, N.J.–(BUSINESS WIRE) February 14, 2017 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating… Details

Epilepsy drug discovered in fish model shows promise in small pediatric clinical trial

03.16 2017.

“Bench-to-bedside” describes research that has progressed from basic science in animal models that has led to therapies used in patients. Details

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression

03.16 2017.

NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received Fast Track designation… Details